Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Innate Pharma has announced the filing of a prospectus supplement with the SEC for a new At-The-Market (“ATM”) program, allowing for the offering of up to $75 million of American Depositary Shares (“ADS”). This program follows the termination of a previous ATM program as of April 19, 2023. The funds from this new initiative are intended for research, development, and working capital. The maximum potential dilution from these offerings could reach approximately 22.97%, based on current share capital. Future offerings will be conducted through an approved sales agreement with Jefferies. Additionally, the 2023 Annual General Meeting on May 12, 2023 may introduce new resolutions for further capital increases, which could impact existing shareholders' stakes.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced its participation in the Van Lanschot Kempen Life Sciences Conference 2023 on April 25-26 in Amsterdam. The company specializes in developing immunotherapies for cancer, leveraging its proprietary ANKET® platform. Key programs include lacutamab, targeting cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to enhance innovation. Headquartered in Marseille, France, Innate Pharma is committed to advancing cancer treatment through its clinical-stage biotechnology.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of shares outstanding and voting rights as of April 1, 2023. The company has a total of 80,222,007 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights stands at 80,979,847, with 80,961,272 exercisable voting rights. These figures comply with the French 'Code de Commerce' and AMF regulations. As a clinical-stage biotechnology firm, Innate focuses on developing immunotherapies for cancer using its proprietary ANKET® platform, partnering with major firms like Sanofi and AstraZeneca to enhance its R&D efforts.